<DOC>
	<DOCNO>NCT00102700</DOCNO>
	<brief_summary>The study document safety efficacy combination ARQ 501 gemcitabine patient treatment-naïve , unresectable , metastatic pancreatic adenocarcinoma .</brief_summary>
	<brief_title>ARQ 501 Combination With Gemcitabine Subjects With Pancreatic Cancer</brief_title>
	<detailed_description>This single-arm , non-randomized study ARQ 501 combination gemcitabine adult patient treatment-naïve , unresectable , metastatic pancreatic adenocarcinoma . The study objective : Primary Objective : - Assess overall response rate ( ORR ) patient treat ARQ 501 combination gemcitabine . Secondary Objectives : - Determine time tumor progression ( TTP ) patient treat ARQ 501 combination gemcitabine - Further characterize safety ARQ 501 combination gemcitabine</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Beta-lapachone</mesh_term>
	<criteria>Have pathologically confirm diagnosis unresectable , metastatic pancreatic adenocarcinoma Be treatmentnaïve . Have measurable disease per RECIST Criteria . Be ≥18 year old . Have Karnofsky Performance Status ( KPS ) ≥70 % . Have estimate life expectancy ≥12 week . Be male nonpregnant , nonlactating female patient . Patients fertile agree use effective barrier method birth control ( e.g. , latex condom , diaphragm , cervical cap ) avoid pregnancy . Have negative serum urine pregnancy test within 7 day prior first dose study drug ( patient female childbearing potential ) . Sign write informed consent form . Have adequate organ function indicate acceptable laboratory value obtain within 7 day prior first dose study drug . Have receive prior therapy treatment pancreatic malignancy ( include chemotherapy , immunotherapy , vaccine , monoclonal antibody , major surgery , irradiation , whether conventional investigational ) . Have active , uncontrolled systemic infection consider opportunistic , life threaten clinically significant time treatment . Are pregnant lactating . Have psychiatric disorder ( ) would interfere consent , study participation , followup . Have severe concurrent disease , , judgment investigator , would make patient inappropriate entry study . Have symptomatic untreated central nervous system ( CNS ) metastasis . Have know hypersensitivity gemcitabine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>pancreas</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>cancer pancreas</keyword>
</DOC>